Maria Fernández López

Dr. Maria Fernández López


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Amparo SantamariaAmparo Santamaria
Amparo Santamaria
CACristina Antón-Maldonado
Cristina Antón-Maldonado
NINataly Ibarra
Nataly Ibarra
MLMaria Fernández López
Maria Fernández López
PGPedro González
Pedro González
RCRafael Carrasco
Rafael Carrasco
Background: Atrial fibrillation (AF) is independently associated with cognitive impairment and dementia through mechanisms extending far beyond traditional cardioembolic stroke risk. However, the relative contribution of distinct pathophysiological pathways and the efficacy of emerging therapeutic interventions for cognitive protection remain incompletely characterized. Objectives: This comprehensive review synthesizes current evidence on the epidemiology, pathophysiological mechanisms, therapeutic interventions (pharmacological, rhythm-control, and digital health), and research priorities addressing the AF–dementia relationship. Methods: A narrative review integrating evidence from observational studies, mechanistic research, randomized controlled trials, systematic reviews, and meta-analyses published through January 2026. Literature sources included MEDLINE/PubMed, major cardiology and neurology journals, and expert consensus statements. Searches used combinations of keywords: "atrial fibrillation," "cognitive decline," "dementia," "silent cerebral infarction," "cerebral hypoperfusion," "direct oral anticoagulants," "catheter ablation," and "digital health." Inclusion criteria encompassed studies examining the AF–cognition association, mechanistic pathways, therapeutic interventions with cognitive outcomes, and digital health technologies in AF management. Heterogeneous study designs prevented quantitative meta-analysis; qualitative synthesis focused on effect sizes, strength of evidence, and clinical implications. Results: Strong epidemiological evidence demonstrates that AF increases relative risk of dementia by 1.4–2.2 fold independently of clinical stroke, with silent cerebral infarction present in 25–40% of AF patients. Multiple interacting pathophysiological mechanisms account for AF-associated cognitive decline: cerebral microembolism (meta-analysis: OR 2.30 for silent infarction on MRI), chronic cerebral hypoperfusion (15–20% reduction in total cerebral blood flow in persistent AF), neuroinflammation, cerebral small vessel disease, and structural brain atrophy. Emerging therapeutic strategies offer complementary neuroprotective mechanisms: direct oral anticoagulants (DOACs)—particularly apixaban and rivaroxaban—reduce dementia risk by approximately 30% compared to warfarin (RR 0.69); rhythm control strategies and catheter ablation demonstrate dementia risk reduction (HR 0.52–0.69); and comprehensive digital health platforms implementing the ABC pathway reduce adverse cardiovascular events by 61% while optimizing adherence and enabling early AF detection. However, evidence-specific to cognitive endpoints remains limited, with the landmark BRAIN-AF trial showing no benefit of low-dose rivaroxaban in low-stroke-risk AF patients—suggesting that non-embolic mechanisms predominate in this population. Conclusions: AF represents a multifaceted threat to brain health requiring a paradigm shift from isolated stroke prevention toward comprehensive heart–brain health optimization. Integration of pharmacological neuroprotection (preferring DOACs), hemodynamic optimization (rhythm control in selected patients), cardiovascular risk factor management, and digital health technologies provides unprecedented opportunity for cognitive preservation. However, critical knowledge gaps persist regarding AF burden thresholds, the relative contribution of competing pathophysiological mechanisms, optimal anticoagulation strategies in low-risk populations, and the long-term cognitive benefits of emerging digital technologies. Prospective randomized clinical trials with cognitive impairment as a primary endpoint, serial neuroimaging, and diverse population representation are urgently needed to validate preventive strategies and refine therapeutic decision-making.

25 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Amparo SantamariaAmparo Santamaria
Amparo Santamaria
CACristina Antón-Maldonado
Cristina Antón-Maldonado
NINataly Ibarra
Nataly Ibarra
MLMaria Fernández López
Maria Fernández López
PGPedro González
Pedro González
RCRafael Carrasco
Rafael Carrasco
Background: Atrial fibrillation (AF) is consistently associated with cognitive impairment and dementia through mechanisms that extend beyond classical cardioembolic stroke. However, the relative contribution of these pathways and the effectiveness of available therapeutic strategies for preserving cognition remain uncertain, as most data come from observational studies with a substantial risk of bias. Objectives: This review narratively synthesizes contemporary evidence on epidemiology, pathophysiological mechanisms, therapeutic strategies—including anticoagulation, rhythm control, and comprehensive risk-factor management—and the role of digital health technologies in the relationship between AF and cognitive decline. Methods: We performed a narrative, PRISMA-informed scoping review of observational cohorts, mechanistic studies, randomized clinical trials, systematic reviews, and meta-analyses published up to January 2026, identified through structured searches in MEDLINE/PubMed and complementary sources. Studies were selected if they examined (i) associations between AF and cognitive impairment or dementia, (ii) mechanistic pathways linking AF to brain injury, (iii) therapeutic interventions with cognitive or brain imaging outcomes, or (iv) digital health technologies applied to AF management. Heterogeneity in study design and outcome assessment precluded meta-analysis; therefore, we provide a qualitative synthesis, explicitly distinguishing observational evidence from randomized data and discussing key sources of confounding. Risk of bias was evaluated using validated tools: ROBINS-I for non-randomized studies, RoB 2.0 for RCTs, Newcastle–Ottawa Scale for observational cohorts, and AMSTAR-2 for systematic reviews. Results: Large population-based cohorts and meta-analyses indicate that AF is associated with a 1.4–2.2-fold higher risk of cognitive impairment or incident dementia, even after adjustment for shared vascular risk factors and exclusion of patients with prior stroke; nevertheless, residual confounding and selection bias cannot be excluded. Silent cerebral infarcts are detected in roughly one-quarter to two-fifths of AF patients without clinical stroke and are themselves associated with cognitive deficits, suggesting that subclinical embolism represents one important, but not exclusive, pathway. Additional mechanisms include chronic cerebral hypoperfusion, neuroinflammation, small vessel disease, and structural brain atrophy, all of which are incompletely disentangled from comorbidities. Observational data suggest that oral anticoagulation, particularly with direct oral anticoagulants (DOACs), is associated with lower rates of dementia compared with no anticoagulation or warfarin, but randomized trials such as BRAIN-AF and GIRAF have not demonstrated a clear cognitive benefit, underlining the low-to-moderate certainty of this evidence. Rhythm-control interventions, especially catheter ablation, are associated with lower dementia incidence in registry studies, yet strong selection effects and short follow-up limit causal inference. Digital health tools and ABC-pathway mobile applications improve cardiovascular outcomes and adherence, although cognitive endpoints remain largely unexplored. Conclusions: AF should be conceptualized as a neurovascular condition with important implications for brain health, rather than a purely cardiac rhythm disorder confined to stroke prevention. A comprehensive heart–brain management strategy that combines optimal anticoagulation, individualized rhythm control, aggressive vascular risk factor modification, routine cognitive screening in older or high-risk patients, and judicious use of digital health technologies may offer the best opportunity for preserving cognition, although rigorous trials with cognitive endpoints are still needed to establish causality.